Shares of Cyclacel Pharmaceuticals Inc. (CYCC) are surging over 53% in pre-market today, after the company announced an agreement with the University of Edinburgh to study fadraciclib (CYC065) and seliciclib (CYC202 or R-roscovitine), its clinical stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease.
from RTT - Before the Bell https://ift.tt/3eEGdBF
via IFTTT
No comments:
Post a Comment